INDEMNITY AGREEMENTIndemnification Agreement • September 15th, 2014 • Tracon Pharmaceuticals Inc • Biological products, (no disgnostic substances) • Delaware
THIS INDEMNITY AGREEMENT (this “Agreement”) dated as of ____________________, is made by and between TRACON PHARMACEUTICALS, INC., a Delaware corporation (the “Company”), and ____________________________ (“Indemnitee”).
LICENCE AGREEMENT between LONZA SALES AG and TRACON PHARMACEUTICALS INCLicense Agreement • September 15th, 2014 • Tracon Pharmaceuticals Inc • Biological products, (no disgnostic substances) • England and Wales
LONZA SALES AG incorporated and registered in Switzerland whose registered office is at Muenchensteinerstrasse 38, CH-4002, Basel, Switzerland (hereinafter referred to as “Lonza”), and
PUBLIC HEALTH SERVICE COOPERATIVE RESEARCH AND DEVELOPMENT AGREEMENT FOR NCI DIVISION OF CANCER TREATMENT AND DIAGNOSIS (DCTD) EXTRAMURAL PHS CLINICAL RESEARCHCooperative Research and Development Agreement • September 15th, 2014 • Tracon Pharmaceuticals Inc • Biological products, (no disgnostic substances) • District of Columbia
This Agreement is based on the model Cooperative Research and Development Agreement (“CRADA”) adopted on December 8, 2010 by the U.S. Public Health Service (“PHS”) Technology Transfer Policy Board for use by components of the National Institutes of Health (“NIH”), the Centers for Disease Control and Prevention (“CDC”), and the Food and Drug Administration (“FDA”), which are agencies of the PHS within the Department of Health and Human Services (“HHS”).
LICENSE AGREEMENT Case Western Reserve University — Tracon Pharmaceuticals Inc.License Agreement • September 15th, 2014 • Tracon Pharmaceuticals Inc • Biological products, (no disgnostic substances) • Ohio
This Agreement (hereinafter “this Agreement”) entered into as of this 2nd day of August, 2006 (“Effective Date”) by and between Case Western Reserve University, an Ohio non-profit corporation, having a principal place of business at 10900 Euclid Avenue, Cleveland, Ohio 44106 (“CASE”) and Tracon Pharmaceuticals, Inc., a Delaware for-profit corporation, having a principal place of business at 4510 Executive Drive, Suite 330, San Diego, California 92121 (“Licensee”).
PUBLIC HEALTH SERVICE COOPERATIVE RESEARCH AND DEVELOPMENT AGREEMENT FOR INTRAMURAL-PHS CLINICAL RESEARCHCooperative Research and Development Agreement • September 15th, 2014 • Tracon Pharmaceuticals Inc • Biological products, (no disgnostic substances) • District of Columbia
This Agreement is based on the model Cooperative Research and Development Agreement (“CRADA”) adopted by the U.S. Public Health Service (“PHS”) Technology Transfer Policy Board for use by components of the National Institutes of Health (“NIH”), the Centers for Disease Control and Prevention (“CDC”), and the Food and Drug Administration (“FDA”), which are agencies of the PHS within the Department of Health and Human Services (“HHS”).
PUBLIC HEALTH SERVICE COOPERATIVE RESEARCH AND DEVELOPMENT AGREEMENT FOR EXTRAMURAL-PHS CLINICAL RESEARCHCooperative Research and Development Agreement • September 15th, 2014 • Tracon Pharmaceuticals Inc • Biological products, (no disgnostic substances) • District of Columbia
also be referred to as Investigational Agent, Study Material, or Study Product. For this Agreement, Investigational Agent means TRC105.
